279
Views
14
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?

, , , , , , & show all
Pages 205-213 | Received 18 Aug 2010, Accepted 15 Nov 2010, Published online: 01 Feb 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

James R. Powell, Stefan Dojcinov, Louise King, Sue Wosniak, Stephen Gerry, Angela Casbard, Hazel Bailey, Eve Gallop-Evans & Tim Maughan. (2013) Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab. Leukemia & Lymphoma 54:5, pages 959-966.
Read now

Articles from other publishers (13)

Hua Yang, Yang Xun, Chao Ke, Kensuke Tateishi & Hua You. (2023) Extranodal lymphoma: pathogenesis, diagnosis and treatment. Molecular Biomedicine 4:1.
Crossref
Na Shen, Yaming Wang, Xuefei Sun, Xueyan Bai, Jinglan He, Qu Cui, Jun Qian, Hong Zhu, Yuedan Chen, Ruixian Xing, Qing Liu, Yuchen Wu, Junhong Li, Wenyuan Lai, Shengjun Sun, Nan Ji & Yuanbo Liu. (2020) Expression of hypoxia‐inducible factor 1α, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors. Brain and Behavior 10:8.
Crossref
Orsolya Matolay & Gábor Méhes. (2019) Sustain, Adapt, and Overcome—Hypoxia Associated Changes in the Progression of Lymphatic Neoplasia. Frontiers in Oncology 9.
Crossref
Domenico Albano, Mattia Bertoli, Marco Battistotti, Carlo Rodella, Massimo Statuto, Raffaele Giubbini & Francesco Bertagna. (2018) Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma. Annals of Nuclear Medicine 32:8, pages 532-541.
Crossref
Zheng-Xiao Zhao, Lin-Wei Lu, Jian Qiu, Qiu-Ping Li, Fei Xu, Bao-Jun Liu, Jing-Cheng Dong & Wei-Yi Gong. (2017) Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis. Oncotarget 9:2, pages 2728-2738.
Crossref
Ayumi Debata, Koichi Yoshida, Kenta Ujifuku, Haruna Yasui, Kensaku Kamada, Daisuke Niino & Takayuki Matsuo. (2016) Hyperglycemia is Associated with Poor Survival in Primary Central Nervous System Lymphoma Patients. Tumori Journal 103:3, pages 272-278.
Crossref
Jing Yang, Wenlu Li, Xin He, Guofei Zhang, Lan Yue & Ying Chai. (2015) VEGF Overexpression Is a Valuable Prognostic Factor for Non-Hodgkin’s Lymphoma Evidence from a Systemic Meta-Analysis. Disease Markers 2015, pages 1-9.
Crossref
Lu Sui, Kun Liu, Wei Shen & Liang Zhang. (2014) Relationships between VEGF protein expression and pathological characteristics of diffuse large B cell lymphoma: a meta-analysis. Tumor Biology 35:9, pages 9085-9093.
Crossref
Soumit K. Basu, Scot C. Remick, Manish Monga & Laura F. Gibson. (2013) Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies. Clinical & Experimental Metastasis 31:2, pages 257-267.
Crossref
Kung-Chao Chang, Wei-Chao Chang, Yao Chang, Liang-Yi Hung, Chien-Hsien Lai, Yu-Min Yeh, Yu-Wei Chou & Chung-Hsuan Chen. (2013) Ran GTPase-Activating Protein 1 Is a Therapeutic Target in Diffuse Large B-Cell Lymphoma. PLoS ONE 8:11, pages e79863.
Crossref
Benjamin Kasenda, Vanessa Haug, Elisabeth Schorb, Kristina Fritsch, Jürgen Finke, Michael Mix, Claudia Hader, Wolfgang A. Weber, Gerald Illerhaus & Philipp T. Meyer. (2013) 18 F-FDG PET Is an Independent Outcome Predictor in Primary Central Nervous System Lymphoma . Journal of Nuclear Medicine 54:2, pages 184-191.
Crossref
F.E. Valles, C.L. Perez-Valles, S. Regalado, R.F. Barajas, J.L. Rubenstein & S. Cha. (2013) Combined Diffusion and Perfusion MR Imaging as Biomarkers of Prognosis in Immunocompetent Patients with Primary Central Nervous System Lymphoma. American Journal of Neuroradiology 34:1, pages 35-40.
Crossref
Prathima ProdduturiPhilip J Bierman. (2012) Current and Emerging Pharmacotherapies for Primary CNS Lymphoma. Clinical Medicine Insights: Oncology 6, pages CMO.S7752.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.